231 related articles for article (PubMed ID: 27067661)
1. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.
Proietti M; Senoo K; Lane DA; Lip GY
Sci Rep; 2016 Apr; 6():24376. PubMed ID: 27067661
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
Senoo K; Proietti M; Lane DA; Lip GY
Am J Med; 2016 Jun; 129(6):600-7. PubMed ID: 26482233
[TBL] [Abstract][Full Text] [Related]
3. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation.
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
Sci Rep; 2017 Sep; 7(1):12066. PubMed ID: 28935868
[TBL] [Abstract][Full Text] [Related]
4. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389
[TBL] [Abstract][Full Text] [Related]
5. Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.
Senoo K; Lip GY
Int J Cardiol; 2016 Oct; 221():379-82. PubMed ID: 27409565
[TBL] [Abstract][Full Text] [Related]
6. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
7. The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
Am J Med; 2018 May; 131(5):574.e13-574.e27. PubMed ID: 29274754
[TBL] [Abstract][Full Text] [Related]
8. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
[TBL] [Abstract][Full Text] [Related]
10. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
Apostolakis S; Lane DA; Buller H; Lip GY
Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
[TBL] [Abstract][Full Text] [Related]
12. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
[TBL] [Abstract][Full Text] [Related]
13. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study.
Chao TF; Lip GYH; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Chen SA
Int J Cardiol; 2018 Mar; 254():157-161. PubMed ID: 29407081
[TBL] [Abstract][Full Text] [Related]
14. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
Lip GY; Frison L; Halperin JL; Lane DA
J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
[TBL] [Abstract][Full Text] [Related]
15. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores.
Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Romiti GF; Marin F; Lip GYH
J Am Heart Assoc; 2018 Sep; 7(18):e009766. PubMed ID: 30371183
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: A PRISMA-compliant article.
Zeng J; Yu P; Cui W; Wang X; Ma J; Zeng C
Medicine (Baltimore); 2020 Jun; 99(25):e20782. PubMed ID: 32569222
[TBL] [Abstract][Full Text] [Related]
17. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
[TBL] [Abstract][Full Text] [Related]
18. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Sanmartin Fernández M; Arribas F; Masjuan J; Barrios V; Cosin-Sales J; Freixa-Pamias R; Recalde E; Pérez-Cabeza AI; Manuel Vázquez Rodríguez J; Ràfols Priu C; Anguita Sánchez M; Lip GYH; Marin F
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):38-46. PubMed ID: 36318457
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.
Lip GYH; Lane DA; Buller H; Apostolakis S
Chest; 2013 Dec; 144(6):1839-1847. PubMed ID: 24009027
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
